A Phase 2 Study of Alisertib (MLN8237) in Recurrent or Persistent Uterine Leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group Study 0231D

OBJECTIVE: This two-stage Phase II study assessed the activity of single agent alisertib in patients with recurrent/persistent uterine leiomyosarcoma (uLMS). METHODS: Eligibility criteria included histologically-confirmed, recurrent or persistent uLMS, age ≥18, 1-2 prior cytotoxic regimens, and RECI...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Gynecol Oncol
Main Authors: Hyman, David M, Sill, Michael W, Lankes, Heather A, Piekarz, Richard, Shahin, Mark S, Ridgway, Mildred R, Backes, Floor, Tenney, Meaghen E, Mathews, Cara A., Hoffman, James S, Aghajanian, Carol, Hensley, Martee L
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5260802/
https://ncbi.nlm.nih.gov/pubmed/28094040
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2016.10.036
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados